Incorporation of therapeutic interventions in physiologically based pharmacokinetic modeling of human clinical case reports of accidental or intentional overdosing with ethylene glycol.
Although occupational uses of the high production volume (HPV) chemical ethylene glycol (EG) have not been associated with adverse effects, there are case reports where humans have either intentionally or accidentally ingested large quantities of EG, primarily from antifreeze. The acute toxicity of EG can proceed through three stages, each associated with a different metabolite: central nervous system depression (ethylene glycol), cardiopulmonary effects associated with metabolic acidosis (glycolic acid), and ultimately renal toxicity (oxalic acid), depending on the total amounts consumed and the effectiveness of therapeutic interventions. A physiologically based pharmacokinetic (PBPK) model developed in a companion paper (Corley et al., 2005). Development of a physiologically based pharmacokinetic model for ethylene glycol and its metabolite, glycolic acid, in rats and humans. Toxicol. Sci., in press 2005) was refined in this study to include clinically relevant treatment regimens for EG poisoning such as hemodialysis or metabolic inhibition with either ethanol or fomepizole. Such modifications enabled the model to describe data from several human case reports, confirming the ability of the previous model to describe the pharmacokinetics of EG and its metabolite, glycolic acid, in humans across a broad range of doses and multiple exposure routes. By integrating the case report data sets with controlled studies in this PBPK model, it was demonstrated that fomepizole, if administered early enough in a clinical situation, can be more effective than ethanol or hemodialysis in preventing the metabolism of EG to more toxic metabolites. Hemodialysis remains an important option, however, if treatment is instituted after a significant amount of EG is metabolized or if renal toxicity has occurred.
Corley
R A
RA
Battelle Pacific Northwest Division, Richland, Washington 99352, USA. rick.corley@pnl.gov
McMartin
K E
KE
D000931:Antidotes / Q000627:therapeutic use*; D004781:Environmental Exposure / Q000009:adverse effects*; D019855:Ethylene Glycol / Q000009:adverse effects / Q000493:pharmacokinetics / Q000506:poisoning; D019317:Evidence-Based Medicine; D006801:Humans; D008658:Inactivation, Metabolic; D007408:Intestinal Absorption; D008954:Models, Biological; D011041:Poisoning / Q000628:therapy; D006435:Renal Dialysis; D018570:Risk Assessment
D000931:Antidotes; D019855:Ethylene Glycol